Gonadorelin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Gonadorelin is a synthetic decapeptide identical in structure to endogenous gonadotropin-releasing hormone (GnRH). It is FDA-approved under the brand names Factrel (diagnostic) and Lutrepulse (pulsatile pump delivery for hypogonadism) and has been used clinically since the 1970s for diagnosing and treating HPG axis disorders.
In contemporary practice, gonadorelin has become a cornerstone of testosterone replacement therapy (TRT) protocols for men who wish to preserve testicular function and fertility. Exogenous testosterone suppresses LH and FSH, causing testicular atrophy and infertility. Concurrent gonadorelin administration - typically via subcutaneous injection 2-3x weekly - mimics the natural GnRH pulses and maintains pituitary-testicular communication, preserving both testicular volume and spermatogenesis.
Gonadorelin is pharmacologically equivalent to kisspeptin-10 in downstream effect (both ultimately trigger LH and FSH) but acts one level lower in the axis - at the pituitary rather than the hypothalamus. This distinction affects dosing strategy: gonadorelin must be administered in pulses, as continuous exposure desensitizes pituitary GnRH receptors and paradoxically suppresses LH (the same mechanism used in GnRH agonist cancer therapies).
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.